Portal de Periódicos da CAPES

Systematic review and economic decision modelling for the prevention and treatment of influenza A and B

2003; NIHR Journals Library; Volume: 7; Issue: 35 Linguagem: Inglês

10.3310/hta7350

2046-4932

David Turner, Allan Wailoo, Karl G. Nicholson, Nicola J. Cooper, Alex J. Sutton, Keith R. Abrams,

Respiratory viral infections research

have no pecuniary relationship with companies making or promoting the use of neuraminidase inhibitors, amantadine and vaccine.Professor Karl Nicholson hereby declares the following potential conflicts of interest: (i) has been paid ad hoc consultancy fees by Hoffman La Roche Pharmaceuticals; (ii) has been paid ad hoc consultancy fees by Wyeth concerning clinical evaluation of live-attenuated, cold-adapted influenza vaccine; (iii) has received reimbursement (travel and hotel accommodation) for attending the international launch of zanamivir in Prague, November 1999, from GlaxoSmithKline; (iv) has received fees for speaking from both GlaxoSmithKline and Hoffman La Roche Pharmaceuticals; (v) has received fees for chairing a symposium from Wyeth; (vi) has received fees for research from (a) Chiron for work on avian influenza vaccines, (b) Aventis Pasteur for work on the epidemiology of RSV in the elderly and (c) Wyeth for work on the epidemiology of influenza in children; (vii) has received consultancy fees from Johnson & Johnson, who no longer have an interest in neuraminidase inhibitors; (viii) has received (prior to the last 3 years) consultancy fees from GlaxoSmithKline in relation to the clinical development of their neuraminidase inhibitor; (ix) his research group has received (prior to the last 3 years)